Medical advances are leading to more new therapeutics but it is small biotech rather than Big Pharma that stands to gain the most. We meet the developers of promising medicines currently breaking into the market to find out whether it is time for the giants to move aside.

We also look at the Gates Foundation’s new collaboration for the research of new TB drugs, ask why Alzheimer’s researchers are turning back to previously discarded drugs, and find out if the discovery of an enzyme that gradually counteracts the efficacy of antipsychotic drugs could lead to the development of a more effective schizophrenia treatment. Moreover, we check in on the progress of major international research projects and investigate changing trends in early phase clinical trials.

Read the latest issue here.

In this issue

Small Players Big Drugs
Big Pharma has never been renowned for innovation. Rather, large pharmaceutical companies have traditionally focused on developing and testing conventional therapeutics. Medical advances are leading to more novel therapeutics and it is small biotech that stands to gain the most.
Click here to read the full article.

Pushing for a Breakthrough
Alzheimer’s disease affects 18 million people worldwide but a cure continues to evade scientists. With access to new data and research platforms our understanding of the illness continues to increase. Dr Nicola Davies finds out how close we are to a breakthrough.
Click here to read the full article.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

New Path
US researchers have discovered an enzyme in the brain of schizophrenia sufferers that counteracts the effects of antipsychotic drugs. Pharmaceutical Technology Focus investigates whether this breakthrough research could lead to a cure.
Click here to read the full article.

Tackling TB
At any given moment, more than 12 million people are suffering from active TB, which is the second leading infectious cause of death worldwide with 1.4 million people dying from it in 2010. The TB Drug Accelerator Project’s Dr Carl Nathan explains how a new partnership aims to find a reliable treatment for the disease.
Click here to read the full article.

Partnerships that Ease the Pain
The Innovative Medicines Initiative plans to call for new proposals for major research projects. Executive Director Michel Goldman outlines how ongoing projects are reporting significant breakthroughs and demonstrating the success of large-scale public-private partnerships.
Click here to read the full article.

Changing Trends
Early-phase clinical trials are crucial for establishing proof of concept and pharmaceutical companies conduct trials every few years. However, with reduced timelines and more detailed patient selection criteria the world of phase I and II trials is rapidly changing.
Click here to read the full article.

Next Issue Preview

Cloud-based computing and virtualisation software hold the key to truly integrated supply chain management. In the next issue we check out the latest IT tools revolutionising the supply chain for pharmaceuticals.

We also find out how security can be managed better to prevent medical cargo theft, and look at the new EC directive for good distribution practice, the push for continuous temperature monitoring, and how the industry can achieve more effective cold chains.

Moreover, we explore logistical problems faced by distributors moving sensitive drugs across the African continent, and look at the challenges of transporting emergency aid and healthcare to conflict zones in the Middle East.

Subscribe for free to get each future issue of Pharma Technology Focus delivered directly to your inbox.

Digital Magazine FAQ

The digital magazine is viewable on any computer with Flash Player installed. It is also viewable on mobile devices, iPhones and iPads, although some features and videos may be disabled.

Read the latest issue.

View the archive of back issues.